CoronaryAtlas logo
CoronaryAtlas
ASCVD Risk Atlas
← Back to table
A

Obesity

Anthropometric & Body CompositionDisease / conditionriskmodifiable
64
evidence score

Also known as: Excess adipose tissue, Excess adipose tissue / obesity, Obesity (BMI ≥30), Obesity (general/BMI-based), body mass index ≥30 kg/m², obese, obesity/increased weight

PREVENT status

Not a PREVENT input variable.

Causal support

trial evidence

Score components
lit volume: 28.7meta-analyses: 20trials: 15genetic: 0MR bonus:

References (740)

38 meta-analyses / systematic reviews

Clinical trials (375)

showing top 60
NCTTitleStatusTypeInterventions
NCT07284511Fully Closed-Loop Glucose Control in Adults With Type 1 Diabetes Using Tirzepatide: a Randomized, Multi-center, Open-label, Non-inferiority, Parallel TrialRECRUITINGINTERVENTIONALTirzepatide, Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM), Carbohydrate Counting
NCT07578584Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Weekly Doses of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and in Participants With Type 1 Diabetes With Overweight or ObesityRECRUITINGINTERVENTIONALNNC0497-0040, Placebo
NCT07221214GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV - GL1DER HIV RCTRECRUITINGINTERVENTIONALSemaglutide (Rybelsus®), Placebo
NCT07218445The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot StudyRECRUITINGINTERVENTIONALTirzepatide, Placebo
NCT07529704Evaluation of a Tailored Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable Families (Bambú Project): Randomized Controlled Trial With a Hybrid Type 1 Effectiveness-implementation DesignRECRUITINGINTERVENTIONALBambú program
NCT07220772An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP GeneRECRUITINGINTERVENTIONALMibavademab
NCT07368777Comparison of Genotype-Based Dietary Counseling Versus Standard Dietary Counseling on Weight Loss and Fat Mass ReductionRECRUITINGINTERVENTIONALGenotype-Based Dietary Counseling, Standard Dietary Counseling
NCT06952348HYPERtension Reduction Through WALKing Stairs Versus Brisk Walking in Individuals With Increased Cardiometabolic Risk - The HYPERWALK Randomized Controlled TrialRECRUITINGINTERVENTIONALStair and brisk walking combined, Brisk walking, Standard care
NCT06966258Inspire HER: Inspiring the Heart and Emotions for Radical HealthRECRUITINGINTERVENTIONALInspire HER Intervention
NCT07219589A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy and Obese ParticipantsRECRUITINGINTERVENTIONALHM17321, Placebo of HM17321
NCT07361887Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular VesiclesRECRUITINGINTERVENTIONALWhite Wine, Red Wine, Water
NCT06988462Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" FoodRECRUITINGINTERVENTIONALBottarga, Comparator
NCT07134335A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) PopulationRECRUITINGINTERVENTIONALUBT251, UBT251, UBT251
NCT07091500Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With ObesityRECRUITINGINTERVENTIONALExercise training, Semaglutide, Therapy Cessation
NCT06619041Harnessing the Power of Social Support for Weight Management: a Randomized Controlled Trial of HealthyTogetherRECRUITINGINTERVENTIONALHealthyTogether
NCT06671119REvision of VSG with Ablation of the Mucosa ProcedureRECRUITINGINTERVENTIONALGastric Mucosal Ablation (GMA)
NCT06517212Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)RECRUITINGINTERVENTIONALTirzepatide
NCT06693934Jockey Club Precision Prevention Programme on Young Onset DiabetesRECRUITINGINTERVENTIONALRisk assessment with biogenetic and clinical test to predict diabetes risk, Oral glucose tolerance test (OGTT) and cardiovascular-kidney-metabolic (CKM) risk factors, Medication
NCT06396416Obesity Management for Kidney TRANSPLANTation: a Vanguard Study for an Innovative Randomized Controlled Trial, Embedded in Routine Care (OK-TRANSPLANT 2)RECRUITINGINTERVENTIONALSemaglutide, Virtual Weight Management Coaching
NCT06446531Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in HispanicsRECRUITINGINTERVENTIONALPlacebo, Rybelsus Tablet, Jardiance 25Mg Tablet
NCT06547775A Randomized, Double-blind and Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 in Chinese Male Participants With Obesity or OverweightRECRUITINGINTERVENTIONALKN069
NCT07447362Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After StudyRECRUITINGINTERVENTIONALStructured Cardiovascular Risk Management
NCT06082063Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesRECRUITINGINTERVENTIONALAspirin tablet, Semaglutide, Sotagliflozin
NCT06271200Effects of Intensive Lifestyle Interventions (ILI) on Weight Loss and Cardiometabolic Risks in Obese Adults With Metabolic Syndrome: A Randomized Clinical TrialRECRUITINGINTERVENTIONALStrategic lifestyle and drug interventions, Control
NCT06239116A Study of RM-718 Weekly Formulation in Healthy Subjects With Obesity and in Patients With Obesity Due to MC4R ImpairmentRECRUITINGINTERVENTIONALPart A: RM-718 or placebo (matched to specific RM-718 dose cohort), Part B: RM-718 or placebo (matched to specific RM-718 dose cohort), Part C: RM-718
NCT05780905Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesRECRUITINGINTERVENTIONALSemaglutide Auto-Injector, Placebo
NCT05987410EffectiVenEss of a Rehabilitation Treatment With Nordic Walking in obEse or oveRweight Diabetic patiEnts With Cardiovascular Disease. The VENERE StudyRECRUITINGINTERVENTIONALNordic Walking (NW), Standard Rehabilitation (SR), Cardiological Counselling (CC)
NCT06060392Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus: Sema-LitRECRUITINGINTERVENTIONALSemaglutide Pill
NCT06055036Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health InterventionRECRUITINGINTERVENTIONALBlack Impact Intervention
NCT05819138Type 1 Diabetes Impacts of Semaglutide on Cardiovascular OutcomesRECRUITINGINTERVENTIONALSemaglutide Pen Injector, Placebo
NCT07272343A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular MechanismsRECRUITINGINTERVENTIONALsemaglutide, caloric restriction
NCT03875625Change of Adipose Tissues and Triglyceride in Obese Patients With Non-alcoholic Fatty Liver Disease After Bariatric Surgery or Life-style InterventionRECRUITINGINTERVENTIONALBariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
NCT07586150Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive TechnologiesNOT YET RECRUITINGINTERVENTIONALSemaglutide (SEMA), Exercise module, Anti-inflammatory diet module
NCT07505459AI-INFORMED PEER-MENTORING BEHAVIORAL INTERVENTION FOR OBESITY AND CARDIOVASCULAR DISEASE PRIMARY PREVENTION IN YOUTHNOT YET RECRUITINGINTERVENTIONALAI-informed behavioral intervention, Standard behavioral intervention, Health Education
NCT06299644Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss Using the Endomina Plicating Device: A Randomized TrialNOT YET RECRUITINGINTERVENTIONALEndoscopic Sleeve Gastroplasty - Belt and Suspenders, Endoscopic Sleeve Gastroplasty - Belt
NCT07276815Gathering of Results in Eligible Asian Obese Populations About Safety and Effectiveness of Overstitch ESG TrialNOT YET RECRUITINGINTERVENTIONALOverStitch NXT Endoscopic Suture System
NCT07693868An NNC6022-0004 Single and Multiple Ascending Dose Study Investigating Safety, Tolerability, Pharmacokinetics, Food Effect and Target Engagement in Healthy Adults Including a Single Cohort in Adults Living With ObesityNOT YET RECRUITINGINTERVENTIONALNNC6022-0004, Placebo
NCT07563699A Prospective, Multicenter, Open Label, Dose Escalation Phase I/IIa Study to Assess the Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes MellitusNOT YET RECRUITINGINTERVENTIONALSG Depot 2 mg, SG Depot 4 mg, SG Depot 6 mg
NCT07668492The Use of 3D Reconstruction, Virtual Reality, and Machine Learning in Addressing Body Image in Bariatric Metabolic Surgery.NOT YET RECRUITINGINTERVENTIONALBody Image Counselling with Virtual Reality
NCT07554638Identifying Therapeutic Mechanisms for Incretin-Based Treatment in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF)NOT YET RECRUITINGINTERVENTIONALTirzepatide
NCT07485764A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Metformin in Combination With Secukinumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese PatientsNOT YET RECRUITINGINTERVENTIONALSecukinumab 300mg s.c., Metformin, Placebo
NCT07566325Effects of Avocado Consumption on Inflammation and Insulin Sensitivity in Adults With Elevated High Sensitivity-C-reactive Protein (Hs-CRP): A Randomized, Controlled Crossover TrialNOT YET RECRUITINGINTERVENTIONALAvocado, Control
NCT07551960Design, Development and Pilot Validation of an Interventional System of the STELA Center for Preventive Medicine to Reduce Modifiable Health Risk Factors in the Adult Population (CPM-STELA)ENROLLING BY INVITATIONINTERVENTIONALSTELA Digital Preventive Medicine Platform, Comprehensive Preventive Health Assessment
NCT07104825Autonomic Neural Blockade During Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial Evaluating Pain and Nausea After Bariatric SurgeryNOT YET RECRUITINGINTERVENTIONALIntraoperative autonomic neural blockade (ANB), Laparoscopic Standard of Care Abdominal Wall Block
NCT07391267Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide - a Randomized Controlled Trial.NOT YET RECRUITINGINTERVENTIONALSemaglutide Oral Tablet, Placebo, Standard medical treatment
NCT07274137A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of MDR-001 Administered Orally Over 52 Weeks in Participants With Overweight or Obesity (MOBILE)NOT YET RECRUITINGINTERVENTIONALMDR-001, Placebo
NCT07209527Evaluation of Truway Health-Sourced Portable Diagnostic Devices for Early Detection of Chronic Conditions in Outpatient Primary Care Settings: A Prospective Interventional StudyENROLLING BY INVITATIONINTERVENTIONALTruway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
NCT07137585Effects of RO7204239 on Insulin Sensitivity, Muscle Composition and Function in Participants Living With Type 2 Diabetes Mellitus and Overweight or Obesity: A Double-blind, Randomized, Placebo-controlled StudyACTIVE NOT RECRUITINGINTERVENTIONALPlacebo, RO7204239
NCT07045272Study on the Construction and Effectiveness of a Digital Behavioral Intervention Program for Overweight and Obese Patients Prior to Assisted Reproductive Technology(ART)TreatmentNOT YET RECRUITINGINTERVENTIONALExperimental
NCT07104383A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants With Type 2 Diabetes Who Are Obese, or OverweightACTIVE NOT RECRUITINGINTERVENTIONALVK2735
NCT06946173Health Interventions For The Prevention Of Obesity In Egyptian Children in Gharbia GovernorateCOMPLETEDINTERVENTIONALhealth program
NCT06926842A Randomized, Double-Blind, Phase 2 Trial of Once-Weekly Petrelintide Compared With Placebo in Participants With Overweight or Obesity and Type 2 DiabetesACTIVE NOT RECRUITINGINTERVENTIONALPetrelintide, Placebo
NCT06915090FIT-COACH: Fitbit Intervention With Coordinated Health Coaching and PCP SupportCOMPLETEDINTERVENTIONALHealth Coach/Fitbit
NCT07429045A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants With Normal Renal Function and Participants With Various Degrees of Renal ImpairmentCOMPLETEDINTERVENTIONALAMG 133
NCT06758856ABC (Additional Betaine and Choline) Study: Effect of Betaine and Choline Intake on Biomarkers of Metabolic Health in HumansCOMPLETEDINTERVENTIONALTrimethylglycine, Eggs, Cellulose
NCT05885074Mechanistic Insights to Weight Loss Maintenance Through SGLT2 InhibitorsWITHDRAWNINTERVENTIONALEmpagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination
NCT06520657Addressing Social Determinants of Health in Child Obesity Treatment Using Community Health Workers: the Role of Parental Bandwidth in Treatment EffectivenessACTIVE NOT RECRUITINGINTERVENTIONALCommunity Health Worker, Child weight management intervention, Standard of Care referral to resources
NCT06712199Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery: a Prospective, Single-center, Randomized, Parallel Controlled StudyNOT YET RECRUITINGINTERVENTIONALoxalidine
NCT07303556Improving the Diagnosis and Treatment of Cardiovascular Diseases in Kazakhstan by Introducing Correction of Metabolism With Glucagon-like Peptide 1 (GLP-1) DrugsACTIVE NOT RECRUITINGINTERVENTIONALTirzepatide (Mounjaro), dapagliflozin, empagliflozin, metformin
NCT06534411Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or BothACTIVE NOT RECRUITINGINTERVENTIONALCagrilintide, Semaglutide, Tirzepatide

Genetic associations (0)

None linked.